Full Breakdown
Incident in the Oval Office During Drug Price Announcement
11/9/2025, 9:39:04 PM
Collapse of a Pharmaceutical Executive
On November 6, 2025, a significant incident occurred in the Oval Office during a press conference led by President Donald Trump, where he announced a new agreement aimed at reducing the prices of weight-loss medications. As the event unfolded, a pharmaceutical executive collapsed while standing behind Trump, prompting immediate medical attention from those present, including Dr. Mehmet Oz, the Administrator of the Centers for Medicare and Medicaid Services.
Eyewitness accounts indicate that the executive appeared unsteady before losing consciousness. Initial reports identified him as Gordon Findlay, the global brand director for Novo Nordisk; however, the company later clarified that Findlay was not present at the event. Instead, the only representatives from Novo Nordisk were CEO Mike Doustdar and Dave Moore, the Executive Vice President for U.S. Operations.
Immediate Response and Medical Attention
As the executive fell, Dr. Oz quickly intervened to prevent him from hitting his head. Other officials, including Health and Human Services Secretary Robert F. Kennedy Jr., also rushed to assist. The press was promptly evacuated from the room while the White House Medical Unit provided care. After approximately 30 minutes, the press conference resumed, with Trump reassuring reporters that the individual was "fine" and receiving medical attention.
White House Press Secretary Karoline Leavitt confirmed the incident, stating, “During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay.”
Details of the Drug Price Agreement
The press conference was centered around a partnership between the Trump administration and pharmaceutical companies Eli Lilly and Novo Nordisk to make GLP-1 weight-loss drugs, including Ozempic, Wegovy, and Zepbound, more affordable. Under the new agreement, these medications are expected to be available at significantly reduced prices, with oral versions projected to cost $149 per month and injectable versions dropping to $245 for Medicare and Medicaid patients.
Dr. Oz expressed optimism about the impact of the agreement, projecting that Americans could collectively lose “135 billion pounds” as a result of increased access to these medications.
Official Statements and Reactions
Following the incident, Dr. Oz praised President Trump for his compassionate response during the emergency. He recounted how Trump took the initiative to comfort the executive's wife during the crisis, stating, “He actually cared that the wife of a man who he has never met before felt in a safer place.”
Eli Lilly CEO David Ricks also addressed the situation, emphasizing the effectiveness of the White House medical staff and confirming that the guest was doing well after the incident.
Conflicting Reports and Clarifications
Despite initial confusion regarding the identity of the collapsed executive, the clarification from Novo Nordisk highlighted the importance of accurate reporting in such incidents. The company reiterated that only their CEO and EVP were present, and the identity of the individual who collapsed remains unconfirmed.
This incident, while alarming, did not overshadow the announcement of the significant drug price reductions aimed at improving access to essential medications for those struggling with obesity.
